EUVIMEDEUVIMED entdecken
Crossref

Characterization and treatment outcomes of rituximab therapy in super-responders and rituximab-refractory pemphigus patients: A single-center retrospective study

Zhili Wu, Jiefeng Jiang, Keyun Duan, Guomin Li, Feng Guo, Jiao Zhang, Ruzeng Xue

Journal of the American Academy of Dermatology · 2026

DOI: 10.1016/j.jaad.2025.12.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026. Verfasst von Zhili Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Southern Medical University, Guangzhou, China; Department of Dermatology, Dermatology Hospital, Southern Medic…. Hauptthemen laut MEDLINE: Rituximab, Pemphigus, Immunologic Factors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rituximab (RTX) is a first-line treatment for pemphigus, yet responses vary. Standardized definitions for super-responder (SR) and rituximab-refractory patient (RRP) are lacking, and their predictive factors remain unclear. OBJECTIVE: To establish definitions for SR and RRP, compare their baseline characteristics, identify predictive factors, and evaluate the safety profile of RTX treatment over 48 weeks. METHODS: This retrospective study analyzed baseline data from patients with pemphigus receiving initial RTX. Univariate and multivariate logistic regression identified independent predictors for SR and RRP. RESULTS: Of 205 patients, 61 (29.8%) were SRs, 55 (26.8%) RRPs, and 89 (43.4%) moderate responders. Independent predictors for SRs were lower baseline Pemphigus Disease Area Index, higher baseline B-cell percentage, and negative direct immunofluorescence for C3. For RRPs, independent predictors were higher initial dose of corticosteroids and history of prior immunosuppressants use. The overall incidence of Treatment-emergent adverse events (TEAEs) within 48 weeks was 29.3%, primarily cutaneous/mucosal infections, with no significant difference among groups. LIMITATIONS: Single center design and limited sample size. CONCLUSION: This study proposes practical definitions for SR and RRP in RTX-treated pemphigus and identifies distinct, readily obtainable baseline predictors, which may facilitate early identification of patients with differing treatment responses, providing personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabPemphigusImmunologic FactorsHumansRetrospective StudiesFemaleMaleMiddle AgedAdultTreatment OutcomeAgedSeverity of Illness IndexDrug Resistance

Stichwörter der Autor:innen

pemphiguspredictorrituximabrituximab-refractorysafetysuper-responder

Substanzen

RituximabImmunologic Factors

Autor:innen und Institutionen

  • The First School of Clinical Medicine, Southern Medical University, Guangzhou, China; Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China.
  • Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China.
  • Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China. Electronic address: xueruzeng@163.com.

Zitieren

APA

Wu, Z., Jiang, J., Duan, K., Li, G., Guo, F., Zhang, J., & Xue, R. (2026). Characterization and treatment outcomes of rituximab therapy in super-responders and rituximab-refractory pemphigus patients: A single-center retrospective study. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.12.030

Vancouver

Wu Z, Jiang J, Duan K, Li G, Guo F, Zhang J, et al. Characterization and treatment outcomes of rituximab therapy in super-responders and rituximab-refractory pemphigus patients: A single-center retrospective study. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2025.12.030

BibTeX
@article{Wu2026,
  author = {Wu, Zhili and Jiang, Jiefeng and Duan, Keyun and Li, Guomin and Guo, Feng and Zhang, Jiao and Xue, Ruzeng},
  title = {Characterization and treatment outcomes of rituximab therapy in super-responders and rituximab-refractory pemphigus patients: A single-center retrospective study},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  doi = {10.1016/j.jaad.2025.12.030}
}
Kostenlos starten →